Cilostazol

Cilostazol (OPC 13013) is a potent and selective inhibitor of phosphodiesterase (PDE) 3A, the isoform of PDE 3 in the cardiovascular system, with an IC50 of 0.2 μM[1][2].

Product Specifications

CAS Number

[73963-72-1]

Product Name Alternative

OPC 13013

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Autophagy; Phosphodiesterase (PDE)

Type

Reference compound

Related Pathways

Autophagy; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/Cilostazol.html

Purity

99.83

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C1NC2=C(C=C(OCCCCC3=NN=NN3C4CCCCC4)C=C2)CC1

Molecular Formula

C20H27N5O2

Molecular Weight

369.46

Precautions

H302, H315, H319, H335

References & Citations

[1]Schr?r K. The pharmacology of cilostazol. Diabetes Obes Metab. 2002 Mar;4 Suppl 2:S14-9.|[2]Minami N, et al. Inhibition of shear stress-induced platelet aggregation by cilostazol, a specific inhibitor of cGMP-inhibited phosphodiesterase, in vitro and ex vivo. Life Sci. 1997;61 (25) :PL 383-9.|[3]Saito S, et al. Cilostazol attenuates hepatic stellate cell activation and protects mice against carbon tetrachloride-induced liver fibrosis. Hepatol Res. 2013 Apr 19.|[4]Ye YL, et al. Cilostazol, a phosphodiesterase 3 inhibitor, protects mice against acute and late ischemic brain injuries.Eur J Pharmacol. 2007 Feb 14;557 (1) :23-31. Epub 2006 Nov 10.